New England Journal of Medicine validates HVRA’s 11-13 week pre-eclampsia screening program

The validation studies have been published confirming confirming HVRA’s pre-eclampsia screening program - as offered through their regional network of Centers for Maternal, Fetal and Placental Health - as the regions first and only provider of an evidence based program to prevent pre-eclampsia. The Center’s for Maternal, Fetal and Placental Health employ an identical multi-variable maternal factor and biomarker screening methodology as detailed in the validation studies.

This program detects 100% of preeclampsia patients delivering before 32 weeks and 75% of preeclampsia patients delivering before 37 weeks. In comparison, American Congress of Obstetricians and Gynecologists recommendations - based on maternal history alone - detected less than 10% of patients that would benefit from aspirin treatment.